StageZero Life Sciences: Early Stage Disease Detection
Test that detects up to ten different cancers in one sample of blood
StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of cancer through blood, the company is uniquely positioned to provide both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing).
StageZero’s full service, telehealth platform includes access to physicians and phlebotomist. Further, they can prescribe and draw samples for individuals and groups. The company also continues to make progress with its mission to eradicate late-stage cancers through early detection.
StageZero’s Detection Test
“The only way you truly change things, is you’ve got to start finding disease early and intervening early because that’s where you change the actual course of the disease,” says Chairman and CEO, James Howard-Tripp.
Its next-generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® detects the cancers that both men and women have in common as well as the cancers that are gender specific.
“It’s a test that amongst the 10 cancers will say it is this cancer and it is not any other and it is not any other disease. That is where we actually beat the world. We don’t see another test out there like that at this point,” says Howard-Tripp.
Currently, Aristotle is focused on cancer however, it will find Alzheimer’s, find major depression and congestive heart failure. It also finds rheumatoid arthritis. “Yes, we’re starting with, with cancer, but we should be able to go so much bigger than that,” says Howard-Tripp.
For more information on StageZero Life Sciences, Ltd. (TSX: SZLS) please click on the request investor info button.